{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T16:07:07Z","timestamp":1726762027575},"reference-count":3,"publisher":"Oxford University Press (OUP)","issue":"S1","license":[{"start":{"date-parts":[[2020,6,26]],"date-time":"2020-06-26T00:00:00Z","timestamp":1593129600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,7,1]]},"abstract":"<jats:p>In the phase III KEYNOTE-204 trial, pembrolizumab significantly improved progression-free survival compared with brentuximab vedotin in patients with relapsed or refractory classic Hodgkin lymphoma (cHL), confirming pembrolizumab as the new standard of care in this setting.<\/jats:p>","DOI":"10.1634\/theoncologist.2020-0561","type":"journal-article","created":{"date-parts":[[2020,6,27]],"date-time":"2020-06-27T08:01:00Z","timestamp":1593244860000},"page":"S18-S19","source":"Crossref","is-referenced-by-count":4,"title":["Pembrolizumab Improves Progression-Free Survival in Relapsed\/Refractory Hodgkin Lymphoma"],"prefix":"10.1093","volume":"25","member":"286","published-online":{"date-parts":[[2020,6,26]]},"reference":[{"key":"2021122511444543100_onco13429-bib-0001","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1056\/NEJMoa1708984","article-title":"Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin's lymphoma","volume":"378","author":"Connors","year":"2018","journal-title":"N Engl J Med"},{"key":"2021122511444543100_onco13429-bib-0002","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1182\/blood.2019000324","article-title":"Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087","volume":"134","author":"Chen","year":"2019","journal-title":"Blood"},{"key":"2021122511444543100_onco13429-bib-0003","author":"Kuruvilla"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1634%2Ftheoncologist.2020-0561","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2020-0561","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2020-0561","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/25\/S1\/S18\/41923054\/oncolo_25_s1_s18.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/25\/S1\/S18\/41923054\/oncolo_25_s1_s18.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,25]],"date-time":"2021-12-25T11:44:54Z","timestamp":1640432694000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/25\/S1\/S18\/6443582"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,26]]},"references-count":3,"journal-issue":{"issue":"S1","published-online":{"date-parts":[[2020,6,26]]},"published-print":{"date-parts":[[2020,7,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2020-0561","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,7,1]]},"published":{"date-parts":[[2020,6,26]]}}}